Cargando…

Bmi1 inhibition enhances the sensitivity of pancreatic cancer cells to gemcitabine

As the standard therapy for pancreatic cancer, gemcitabine shows limited efficacy in pancreatic cancer patients because of chemoresistance. Aberrant expression of Bmi1 has been reported to activate multiple growth-regulatory pathways and confer anti-apoptotic abilities to many cancer cells. However,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yin, Tao, Zhang, Zhengle, Cao, Bin, Duan, Qingke, Shi, Pengfei, Zhao, Hengqiang, Camara, Soriba Naby, Shen, Qiang, Wang, Chunyou
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5095068/ https://www.ncbi.nlm.nih.gov/pubmed/27177084 http://dx.doi.org/10.18632/oncotarget.9293

Ejemplares similares

Up‐regulation of glycolysis promotes the stemness and EMT phenotypes in gemcitabine‐resistant pancreatic cancer cells
por: Zhao, Hengqiang, et al.
Publicado: (2017)

ROS/KRAS/AMPK Signaling Contributes to Gemcitabine-Induced Stem-like Cell Properties in Pancreatic Cancer
por: Zhao, Hengqiang, et al.
Publicado: (2019)

Mechanistic Evaluation and Translational Signature of Gemcitabine-induced Chemoresistance by Quantitative Phosphoproteomics Analysis with iTRAQ Labeling Mass Spectrometry
por: Duan, Qingke, et al.
Publicado: (2017)

Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentially potentiate the motility of pancreatic cancer cells
por: Li, Hehe, et al.
Publicado: (2019)

Correction: Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentially potentiate the motility of pancreatic cancer cells
por: Li, Hehe, et al.
Publicado: (2023)

High glucose promotes pancreatic cancer cells to escape from immune surveillance via AMPK-Bmi1-GATA2-MICA/B pathway
por: Duan, Qingke, et al.
Publicado: (2019)

Astaxanthin inhibits gemcitabine-resistant human pancreatic cancer progression through EMT inhibition and gemcitabine resensitization
por: Yan, Tao, et al.
Publicado: (2017)

Hypoxia potentiates gemcitabine-induced stemness in pancreatic cancer cells through AKT/Notch1 signaling
por: Zhang, Zhengle, et al.
Publicado: (2018)

Dendritic Cells Loaded with Pancreatic Cancer Stem Cells (CSCs) Lysates Induce Antitumor Immune Killing Effect In Vitro
por: Yin, Tao, et al.
Publicado: (2014)

Inhibition of Neddylation Modification Sensitizes Pancreatic Cancer Cells to Gemcitabine
por: Li, Hua, et al.
Publicado: (2017)

Cancer Stem-Like Cells Enriched in Panc-1 Spheres Possess Increased Migration Ability and Resistance to Gemcitabine
por: Yin, Tao, et al.
Publicado: (2011)

Valproic acid sensitizes pancreatic cancer cells to natural killer cell-mediated lysis by upregulating MICA and MICB via the PI3K/Akt signaling pathway
por: Shi, Pengfei, et al.
Publicado: (2014)

Wogonin increases gemcitabine sensitivity in pancreatic cancer by inhibiting Akt pathway
por: Zhang, Tianli, et al.
Publicado: (2022)

Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine
por: DUONG, HONG-QUAN, et al.
Publicado: (2013)

Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway
por: Zhou, Yunjiang, et al.
Publicado: (2019)

YAP Inhibition by Resveratrol via Activation of AMPK Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine
por: Jiang, Zhengdong, et al.
Publicado: (2016)

Low Concentrations of Metformin Selectively Inhibit CD133(+) Cell Proliferation in Pancreatic Cancer and Have Anticancer Action
por: Gou, Shanmiao, et al.
Publicado: (2013)

Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabine
por: Duong, Hong-Quan, et al.
Publicado: (2013)

STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer
por: Liu, Chao, et al.
Publicado: (2019)

Gold Nanoparticles sensitize pancreatic cancer cells to gemcitabine
por: Huai, Yanyan, et al.
Publicado: (2019)

Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer
por: Blaauboer, Amber, et al.
Publicado: (2020)

Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair()()
por: Kausar, Tasneem, et al.
Publicado: (2015)

YAP Inhibition by Nuciferine via AMPK-Mediated Downregulation of HMGCR Sensitizes Pancreatic Cancer Cells to Gemcitabine
por: Zhou, Ling, et al.
Publicado: (2019)

Harmine suppresses the proliferation of pancreatic cancer cells and sensitizes pancreatic cancer to gemcitabine treatment
por: Wu, Lin-Wen, et al.
Publicado: (2019)

Malnutrition prevalence and associated biochemical factors among drug-resistance tuberculosis (DR-TB) patients at key treatment sites in Conakry City, Republic of Guinea
por: Magassouba, Aboubacar Sidiki, et al.
Publicado: (2021)

Disrupting glutamine metabolic pathways to sensitize gemcitabine-resistant pancreatic cancer
por: Chen, Ru, et al.
Publicado: (2017)

A Novel Ferroptosis-Related Signature for Prediction of Prognosis, Immune Profiles and Drug Sensitivity in Hepatocellular Carcinoma Patients
por: Zhao, Chuanbing, et al.
Publicado: (2022)

Inhibition of SIRT1 combined with gemcitabine therapy for pancreatic carcinoma
por: Gong, Dao-Jun, et al.
Publicado: (2013)

Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity
por: Fraunhoffer, Nicolas Alejandro, et al.
Publicado: (2022)

Inhibition of glucose turnover by 3-bromopyruvate counteracts pancreatic cancer stem cell features and sensitizes cells to gemcitabine
por: Isayev, Orkhan, et al.
Publicado: (2014)

A novel signature of combing cuproptosis- with ferroptosis-related genes for prediction of prognosis, immunologic therapy responses and drug sensitivity in hepatocellular carcinoma
por: Zhao, Chuanbing, et al.
Publicado: (2022)

Alterations of oral microbiota are associated with the development and severity of acute pancreatitis
por: Liu, Yiting, et al.
Publicado: (2023)

Pancreatic Cancer Chemoresistance to Gemcitabine
por: Amrutkar, Manoj, et al.
Publicado: (2017)

Silencing of B7-H3 increases gemcitabine sensitivity by promoting apoptosis in pancreatic carcinoma
por: ZHAO, XIN, et al.
Publicado: (2013)

Exosomal ACADM sensitizes gemcitabine-resistance through modulating fatty acid metabolism and ferroptosis in pancreatic cancer
por: Yang, Yuhan, et al.
Publicado: (2023)

Gemcitabine inhibits immune escape of pancreatic cancer by down regulating the soluble ULBP2 protein
por: Lin, Xiansheng, et al.
Publicado: (2016)

Suppression of pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer to gemcitabine and 5FU, and inhibits the formation of pancreatic cancer stem like cells
por: Cho, Jae Hee, et al.
Publicado: (2017)

Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition
por: IOANNOU, NIKOLAOS, et al.
Publicado: (2016)

Gemcitabine plus concurrent irreversible electroporation vs gemcitabine alone for locally advanced pancreatic cancer
por: Ma, Yang-Yang, et al.
Publicado: (2020)

P300 inhibition enhances gemcitabine-induced apoptosis of pancreatic cancer
por: Ono, Hiroaki, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_9438438ngf1lr2mau5d2tjm39f